Portola Pharma (PTLA) Tops Q3 EPS by 5c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- Wall St subdued as markets pause after S&P record high; data, Mideast in focus
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Portola Pharmaceuticals Reports Third Quarter 2017 Financial Results and Provides Corporate Update
November 6, 2017 4:01 PM ESTSOUTH SAN FRANCISCO, Calif., Nov. 06, 2017 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals Inc.® (Nasdaq: PTLA) will today report financial results and provide a corporate update for the quarter ended September 30, 2017.
Following FDA approval of our first product, Bevyxxa, our team has been working diligently to bring this important new medicine to patients in need, and we are pleased to report good progress with the FDA on achieving product release, said Bill Lis, chief executive officer of Portola. We are also continuing to advance AndexXa, the first-ever Factor Xa inhibitor antidote. This treatment is... More
